Business Description
Energenesis Biomedical Co Ltd
ISIN : TW0006657000
Share Class Description:
TPE:6657: Ordinary SharesTotal Employee Number:
29Description
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 56.48 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 36.6 | |||||
Beneish M-Score | -3.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.2 | |||||
3-Year EBITDA Growth Rate | 9.5 | |||||
3-Year EPS without NRI Growth Rate | 9.6 | |||||
3-Year FCF Growth Rate | 10.6 | |||||
3-Year Book Growth Rate | 4.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.47 | |||||
9-Day RSI | 42.6 | |||||
14-Day RSI | 43.26 | |||||
3-1 Month Momentum % | -15.97 | |||||
6-1 Month Momentum % | -16.37 | |||||
12-1 Month Momentum % | -41.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.91 | |||||
Quick Ratio | 19.89 | |||||
Cash Ratio | 19.3 | |||||
Days Inventory | 168.83 | |||||
Days Sales Outstanding | 44.35 | |||||
Days Payable | 56.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.3 | |||||
Shareholder Yield % | -12.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 76 | |||||
Operating Margin % | -3587.11 | |||||
Net Margin % | -3367.24 | |||||
EBITDA Margin % | -3067.08 | |||||
FCF Margin % | -2928.5 | |||||
OCF Margin % | -2898.23 | |||||
ROE % | -27.23 | |||||
ROA % | -26.1 | |||||
ROIC % | -289.33 | |||||
3-Year ROIIC % | 8.44 | |||||
ROC (Joel Greenblatt) % | -326.79 | |||||
ROCE % | -26.96 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 405.74 | |||||
PB Ratio | 3.47 | |||||
Price-to-Tangible-Book | 3.47 | |||||
EV-to-EBIT | -8.84 | |||||
EV-to-EBITDA | -9.69 | |||||
EV-to-Revenue | 297.1 | |||||
EV-to-FCF | -10.87 | |||||
Price-to-GF-Value | 0.69 | |||||
| Price-to-Net-Current-Asset-Value | 3.82 | |||||
| Price-to-Net-Cash | 3.95 | |||||
Earnings Yield (Greenblatt) % | -11.31 | |||||
FCF Yield % | -7.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Energenesis Biomedical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 7.674 | ||
| EPS (TTM) (NT$) | -2.936 | ||
| Beta | 0.4697 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 33.32 | ||
| 14-Day RSI | 43.26 | ||
| 14-Day ATR (NT$) | 1.257327 | ||
| 20-Day SMA (NT$) | 35.8925 | ||
| 12-1 Month Momentum % | -41.67 | ||
| 52-Week Range (NT$) | 31.5 - 64.8 | ||
| Shares Outstanding (Mil) | 87.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Energenesis Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Energenesis Biomedical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Energenesis Biomedical Co Ltd Frequently Asked Questions
What is Energenesis Biomedical Co Ltd(TPE:6657)'s stock price today?
The current price of TPE:6657 is NT$35.30. The 52 week high of TPE:6657 is NT$64.80 and 52 week low is NT$31.50.
When is next earnings date of Energenesis Biomedical Co Ltd(TPE:6657)?
The next earnings date of Energenesis Biomedical Co Ltd(TPE:6657) is .
Does Energenesis Biomedical Co Ltd(TPE:6657) pay dividends? If so, how much?
Energenesis Biomedical Co Ltd(TPE:6657) does not pay dividend.
Press Release
Articles on Energenesis Biomedical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers